No Pharma Money
News & Reports
News October 14, 2019

The Week in Review in Prescription Drug Pricing

By P4ADNow Team

If the Nats can make the NLCS without Bryce Harper, surely Washington can pass drug pricing reform by the end of the year.

1. Patients Win in California!

  • California became the first state in the country to ban abusive pay-for-delay deals that keep low-cost generics off the market and out of patients’ hands. — (FiercePharma)

2. Big Price Increases, Because ?‍♂️

  • The top seven best-selling drugs experienced price increases with no reasonable justification. YOLO, said Pharma in response. — (Endpoints News)

3. Patient Groups Paid Off

  • Some of Big Pharma’s biggest players shoveled $650 million into hundreds of nonprofits last year — including those campaigning against federal drug pricing legislation. Things that make you go hmmm. — (Bloomberg Government)

4. Raising Her Voice

  • P4AD advocate and drug pricing hero Sa’Ra Skipper and her little sister live with type 1 diabetes. Sa’Ra almost lost her sister after they shared their insulin supply, and now, she’s speaking out. — (Patients For Affordable Drugs)

5. Bye, Felicia

  • BIO’s Jim Greenwood is resigning after the 2020 election. We hope the next BIO chief will bring drug pricing solutions to the table — instead of standing in the way. — (FierceBiotech)

Stay Connected

Stay informed about the latest campaigns, policy developments, and ways to help lower prescription drug prices.